Industry
Biotechnology
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Loading...
Open
1.55
Mkt cap
39M
Volume
1.8K
High
1.57
P/E Ratio
-5.07
52-wk high
3.30
Low
1.52
Div yield
N/A
52-wk low
1.46
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.